China Biologic Products (CBPO) Tops Q2 EPS by 10c

China Biologic Products (NASDAQ: CBPO) reported Q2 EPS of $1.26, $0.10 better than the analyst estimate of $1.16. Revenue for the quarter came in at $91.4 million versus the consensus estimate of $87.6 million.

Financial Outlook

For the full year of 2016, the Company reiterates its full year forecast of total sales growth of 21% to 23% in RMB terms and non-GAAP adjusted net income growth of 24% to 26% in RMB terms over 2015 financial results. This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.21 = $1.00 based on weighted average quarterly exchange rates in 2015 in translating 2015 financial results, the Company expects that the total sales and non-GAAP adjusted net income in USD terms in 2016 will be adversely affected by the foreign currency translation impact.

For earnings history and earnings-related data on China Biologic Products (CBPO) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Spruce Biosciences (SPRB) PT Lowered to $144 at Citizens on Higher OpEx, Net Loss
• HSBC Upgrades Pegatron Corp. (4938:TT) to Hold